Ceragenix Enters Into Second Exclusive Option to License Agreement for Antimicrobial Medical Device
May 11, 2009 07:17 ET
|
Ceragenix Pharmaceuticals
DENVER, May 11, 2009 -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into an...
Ceragenix Achieves 200 Days of Antimicrobial Efficacy On Treated Silicone Medical Device
May 04, 2009 07:12 ET
|
Ceragenix Pharmaceuticals
DENVER, May 04, 2009 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that preclinical testing...
Ceragenix and MAST BioSurgery Enter Into Joint Development Agreement for New Antimicrobial Surgical Products
April 29, 2009 07:12 ET
|
Ceragenix Pharmaceuticals
DENVER, Apr 29, 2009 -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into a...
Ceragenix and Pediapharm Enter Into Distribution and Supply Agreement for EpiCeram(R)
February 25, 2009 07:13 ET
|
Ceragenix Pharmaceuticals
DENVER and MONTREAL, Feb 25, 2009 -- Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has...
Japanese Researchers Find CSA-13 May be Useful for Prevention and Treatment of Dental Caries and Periodontal Disease
February 23, 2009 07:12 ET
|
Ceragenix Pharmaceuticals
DENVER, Feb 23, 2009 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that in vitro research...
Ceragenix Achieves 120 Days of Antimicrobial Efficacy on Treated Silicone Medical Device
February 03, 2009 07:15 ET
|
Ceragenix Pharmaceuticals
DENVER, Feb 03, 2009 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that preclinical testing...
Promius Pharma, LLC Launches EpiCeram(R) Skin Barrier Emulsion
October 14, 2008 08:20 ET
|
Ceragenix Pharmaceuticals
DENVER, Oct 14, 2008 -- Ceragenix Pharmaceuticals, Inc., (OTCBB:CGXP) today announced that Promius Pharma, LLC, a wholly owned subsidiary of Dr. Reddy's Laboratories (NYSE:RDY) ("DRL") launched its...
Ceragenix Satisfies Conditions for $1 Million Milestone Payment under Supply and Distribution Agreement
September 22, 2008 12:25 ET
|
Ceragenix Pharmaceuticals
DENVER--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that it had satisfied the conditions...
Ceragenix Announces Results of a Comparison Study of the Safety and Efficacy of EpiCeram(R) Cream for the Treatment of Mild to Moderate Pediatric Atopic Dermatitis
May 20, 2008 08:26 ET
|
Ceragenix Pharmaceuticals
DENVER, May 20, 2008 -- Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its investigator-blinded study comparing the safety and efficacy of EpiCeram(R) Skin Barrier...
CeraShield(TM) Coated Urinary Catheters Provide Superior Protection Against Bacterial Colonization Compared to Leading Brands in Preclinical Testing
April 29, 2008 08:17 ET
|
Ceragenix Pharmaceuticals
DENVER, Apr 29, 2008 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a biopharmaceutical and medical device company focused on infectious disease and dermatology, today presented...